Grant from the ‘EU Joint Programme – Neurodegenerative Disease Research’ (JPND) provides €1.45M in funding for the program
AC Immune’s proprietary MorphomerTM platform continues accelerating development of first- and best-in-class small molecule therapeutics and diagnostics for neurodegenerative diseases
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that a highly competitive European Union grant has been awarded to support the partnership between AC Immune and the JPND ImageTDP-43 consortium to accelerate development of the Company’s first-in-class TDP-43 positron emission tomography (PET) tracer.